- Home
- TROO vs MCRB Comparison
TROO vs MCRB Comparison
Compare TROO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- MCRB
- Stock Information
- Founded
- TROO 2005
- MCRB 2010
- Country
- TROO Hong Kong
- MCRB United States
- Employees
- TROO N/A
- MCRB N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- TROO Technology
- MCRB Health Care
- Exchange
- TROO Nasdaq
- MCRB Nasdaq
- Market Cap
- TROO 166.5M
- MCRB 141.9M
- IPO Year
- TROO N/A
- MCRB 2015
- Fundamental
- Price
- TROO $1.44
- MCRB $0.80
- Analyst Decision
- TROO
- MCRB Buy
- Analyst Count
- TROO 0
- MCRB 4
- Target Price
- TROO N/A
- MCRB $5.63
- AVG Volume (30 Days)
- TROO 61.7K
- MCRB 875.0K
- Earning Date
- TROO 11-15-2024
- MCRB 03-04-2025
- Dividend Yield
- TROO N/A
- MCRB N/A
- EPS Growth
- TROO N/A
- MCRB N/A
- EPS
- TROO N/A
- MCRB N/A
- Revenue
- TROO $4,344,000.00
- MCRB $126,325,000.00
- Revenue This Year
- TROO N/A
- MCRB N/A
- Revenue Next Year
- TROO N/A
- MCRB N/A
- P/E Ratio
- TROO N/A
- MCRB N/A
- Revenue Growth
- TROO 14.77
- MCRB 12856.41
- 52 Week Low
- TROO $0.73
- MCRB $0.54
- 52 Week High
- TROO $4.89
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- TROO 38.81
- MCRB 46.38
- Support Level
- TROO $1.41
- MCRB $0.81
- Resistance Level
- TROO $1.57
- MCRB $0.84
- Average True Range (ATR)
- TROO 0.12
- MCRB 0.04
- MACD
- TROO 0.01
- MCRB 0.00
- Stochastic Oscillator
- TROO 30.03
- MCRB 45.58
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.